SCHEDULE: RA Capital Maintains 11.2% Stake in Fulcrum Therapeutics

RA Capital Management and its affiliates reported a continued 11.2% beneficial ownership stake in Fulcrum Therapeutics, holding 6,053,960 common shares.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") reported beneficial ownership of 6,053,960 shares of Fulcrum Therapeutics, Inc. common stock.
• This represents 11.2% of the company's outstanding common stock, based on 54,118,438 shares outstanding as of October 22, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on October 29, 2025.
• RA Capital Healthcare Fund, L.P. also holds pre-funded warrants exercisable for an aggregate of up to 8,500,000 shares of common stock, but these warrants contain a beneficial ownership blocker that precludes exercise if it would result in ownership exceeding 9.99% of the common stock outstanding.
• The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G/A and disclaim beneficial ownership of the securities for any purpose other than determining their obligations under Section 13(d) of the Act.

Sentiment

Score: 6

Explanation: The filing indicates a stable, significant institutional ownership by a specialized healthcare fund, which is generally positive. However, it's an amendment showing no change in percentage, and the beneficial ownership blocker on warrants introduces a slight limitation on potential future influence.

Positives

• A significant institutional investor, RA Capital Management, maintains a substantial stake, indicating continued confidence in Fulcrum Therapeutics.
• The passive nature of the filing (Schedule 13G) suggests the investment is not for control purposes, which can be viewed positively by existing management and other shareholders.

Negatives

• No new significant investment or increase in the ownership stake is reported, as this is an amendment to a previous filing.
• The beneficial ownership blocker on the pre-funded warrants limits RA Capital's immediate ability to increase its voting power beyond the 9.99% threshold, potentially capping their influence.

Risks

• The existence of pre-funded warrants with a beneficial ownership blocker could indicate a strategic limitation on the investor's influence or a regulatory constraint on their ability to increase their stake beyond a certain threshold.

Future Outlook

NA

Industry Context

RA Capital Management is a prominent healthcare and life sciences investment firm. Their continued significant stake in Fulcrum Therapeutics, a biotechnology company, aligns with their specialization in the sector. Such an investment by a dedicated healthcare fund often signals a belief in the long-term potential of the company's pipeline or technology within the competitive biotech landscape.

Stakeholder Impact

• Shareholders: The continued significant stake by a major institutional investor like RA Capital may provide a level of confidence and stability in the company's long-term prospects.
• Management: The passive nature of the 13G filing (not seeking control) suggests RA Capital is not actively challenging management, which can foster a stable operational environment.

Key Dates

Recommendation

The filing is an amendment to a Schedule 13G, indicating a passive, long-term investment by RA Capital Management. It reports a continued 11.2% stake, with no new material changes in ownership percentage or intent. While the presence of a significant institutional investor is generally positive, this specific filing does not introduce new information that would warrant a change in investment thesis. The beneficial ownership blocker on warrants is a pre-existing condition. Therefore, a 'hold' recommendation is appropriate as there's no fresh catalyst for 'buy' or 'sell' based solely on this ownership disclosure.

Keywords

Fulcrum Therapeutics, RA Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, Healthcare Fund, Equity Stake